Initial Experience on Rifampin and Pyrazinamide vs Isoniazid in the Treatment of Latent Tuberculosis Infection Among Patients With Silicosis in Hong Kong

Chest - United States
doi 10.1378/chest.124.6.2112
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2013English

Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Treatment Completion for Latent Tuberculosis Infection: A Retrospective Cohort Study Comparing 9 Months of Isoniazid, 4 Months of Rifampin and 3 Months of Isoniazid and Rifapentine

BMC Infectious Diseases
Infectious Diseases
2017English

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2016English

Prevalence of Latent Tuberculosis Infection Among Patients With Lung Cancer

Respirology
PulmonaryRespiratory Medicine
2019English

Benefit of Treatment of Latent Tuberculosis Infection in Individual Patients

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2015English

Adherence to a COPD Treatment Guideline Among Patients in Hong Kong

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2017English

Studies in Tuberculosis in Hong Kong

Journal of Hygiene
1938English

Experiments on Ascaris Infection in Hong Kong

Nature
Multidisciplinary
1917English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy